Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shield Therapeutics PLC (GB:STX)
LSE:STX
RESEARCH TOOLSreports
Holding GB:STX?
Track your performance easily
STX Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range1.06p - 12.85p
Previous Close4.3p
Volume1.96M
Average Volume (3M)4.83M
Market Cap
£33.63M
Enterprise Value36.44M
Total Cash (Recent Filing)£2.82M
Total Debt (Recent Filing)£5.63M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding775,429,360
10 Day Avg. Volume4,928,505
30 Day Avg. Volume4,828,176
Standard Deviation0.28
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)-143.33
Price to Sales (P/S)2.83
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
2.00pPrice Target Upside-53.49% Downside
Rating ConsensusHold
Number of Analyst Covering1
Shield Therapeutics News
PremiumCompany Announcements
Shield Therapeutics Sees Strong Revenue Growth
PremiumCompany Announcements
Shield Therapeutics’ Iron Drug Wins Canada Approval
PremiumCompany Announcements
Shield Therapeutics Readies H1 2024 ResultsPremiumCompany Announcements
Shield Therapeutics Sees Surge in Q2 Revenue
PremiumCompany Announcements
Shield Therapeutics Appoints New Interim CEO
PremiumCompany Announcements
Shield Therapeutics AGM Yields Strong Support
PremiumCompany Announcements
Shield Therapeutics Eyes Expansion in Korea
PremiumCompany Announcements
Shield Therapeutics Reports Revenue Surge and Reduced LossesOptions Prices
Currently, No data available
---
Ownership Overview
3.84% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
96.16% Public Companies and
Individual Investors
STX FAQ
What was Shield Therapeutics PLC’s price range in the past 12 months?
Shield Therapeutics PLC lowest share price was 1.06p and its highest was 12.85p in the past 12 months.
What is Shield Therapeutics PLC’s market cap?
Currently, no data Available
When is Shield Therapeutics PLC’s upcoming earnings report date?
Shield Therapeutics PLC’s upcoming earnings report date is Apr 24, 2025 which is in 216 days.
How were Shield Therapeutics PLC’s earnings last quarter?
Shield Therapeutics PLC released its earnings results on Sep 04, 2024. The company reported -0.015p earnings per share for the quarter, missing the consensus estimate of N/A by -0.015p.
Is Shield Therapeutics PLC overvalued?
According to Wall Street analysts Shield Therapeutics PLC’s price is currently Overvalued.
Does Shield Therapeutics PLC pay dividends?
Shield Therapeutics PLC does not currently pay dividends.
What is Shield Therapeutics PLC’s EPS estimate?
Shield Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shield Therapeutics PLC have?
Shield Therapeutics PLC has 782,056,400 shares outstanding.
What happened to Shield Therapeutics PLC’s price movement after its last earnings report?
Shield Therapeutics PLC reported an EPS of -0.015p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -15.094%.
Which hedge fund is a major shareholder of Shield Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:STX
---
Shield Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-57.53%
12-Months-Change
Fundamentals
Return on Equity
-264.41%
Trailing 12-Months
Asset Growth
12.87%
Trailing 12-Months
Company Description
Shield Therapeutics PLC
Shield Therapeutics PLC is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. The company's operating segments which is based on key products include Feraccru, used as a novel oral treatment for iron deficiency anemia in patients, which is commercially available and PT20 used in treating hyperphosphatemia, which is in its last stage of completion. It generates maximum revenue from Feraccru segment.
---
STX Stock 12 Month Forecast
Average Price Target
2.00p
▼(-53.49% Downside)
Technical Analysis
---